-
公开(公告)号：US20240327535A1
公开(公告)日：2024-10-03
申请号：US18741705
申请日：2024-06-12
发明人： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/68 , A61P35/00
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
摘要： Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US12043670B2
公开(公告)日：2024-07-23
申请号：US17339549
申请日：2021-06-04
发明人： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/68 , A61P35/00
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
摘要： Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US10889866B2
公开(公告)日：2021-01-12
申请号：US15755225
申请日：2016-08-30
发明人： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC分类号： C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806 , C12Q1/6841
摘要： Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US11998544B2
公开(公告)日：2024-06-04
申请号：US17059876
申请日：2019-05-31
发明人： Ermira Pazolli , Silvia Buonamici , James Palacino , Michael Seiler , Ping Zhu , Evan Barry , Lihua Yu
IPC分类号： A61K31/496 , A61K35/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/39 , A61K39/395 , A61K47/68
CPC分类号： A61K31/496 , A61K35/17 , A61K38/191 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K47/6803 , A61K2039/6031 , A61K2039/6037 , A61K2039/6056 , A61K2039/6081
摘要： This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：US11761045B2
公开(公告)日：2023-09-19
申请号：US17098940
申请日：2020-11-16
发明人： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC分类号： C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806 , C12Q1/6841
CPC分类号： C12Q1/6886 , A61K31/4545 , A61K31/495 , A61K31/55 , A61P35/00 , C12Q1/025 , C12Q1/6806 , C12Q1/6841 , C12Q2600/106 , C12Q2600/158
摘要： Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US20190337921A1
公开(公告)日：2019-11-07
申请号：US16349508
申请日：2017-11-22
发明人： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu , Lorna Helen Mitchell , Nicholas Larsen , Nathalie Rioux
IPC分类号： C07D401/06 , C07D209/08 , C07D401/14 , A61P35/00
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
发明人： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC分类号： C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC分类号： C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
摘要： Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20210130909A1
公开(公告)日：2021-05-06
申请号：US17098940
申请日：2020-11-16
发明人： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC分类号： C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806
摘要： Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US10851065B2
公开(公告)日：2020-12-01
申请号：US15713107
申请日：2017-09-22
发明人： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu
IPC分类号： A01N43/00 , A01N43/46 , A61K31/55 , C07D231/56 , C07D403/12 , C07D471/14 , C07D403/06 , C07D401/06 , C07D401/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：US11524009B2
公开(公告)日：2022-12-13
申请号：US16760313
申请日：2018-10-30
发明人： Daniel Aird , Laura Corson , Ping Zhu , Markus Warmuth , Silvia Buonamici , Peter Gerard Smith , Peter Fekkes
IPC分类号： A61K31/496 , A61P35/00 , A61K31/05 , A61K31/11 , A61K31/166 , A61K31/343 , A61K31/352 , A61K31/395 , A61K31/404 , A61K31/426 , A61K31/4355 , A61K31/4725 , A61K31/495 , A61K31/5355
摘要： The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.028 秒)
